跳至主要内容
临床试验/ITMCTR1900002613
ITMCTR1900002613尚未招募未知

Therapeutic Effect of Back-shu Point Catgut Embedding in Spleen-stomach Deficiency Type I and II Myasthenia Gravis

The First Affiliated Hospital of Guangzhou University of Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 75(—)
性别
All

入选标准

  • 1. Diagnosed with Myasthenia Gravis based on the diagnostic criteria of Practical internal science (Peoples Medical Publishing House The 15th edition)and patients with MG belonging to the the modifed Osseman III type;
  • 2. Diagnosed with Chinese medical diagnosis of flaccidity fitting to the differentiation standard of spleen-stomach deficiency type;
  • 3. Aged 18 to 75-year-old;
  • 4. Sign informed consent.

排除标准

  • 1. Osseman III, IV, V;
  • 2. Familial MG, congenital myasthenic syndrome and drug (D-penicillamine, interferon induced by MG, etc.);
  • 3. Patients who were nursing or pregnant;
  • 4. Patients who had comorbid diseases such as cerebrovascular diseases, renal insufficiency, hematopoietic system diseases, and psychiatric diseases;
  • 5. Patients who has contraindications for embedding;
  • 6. Allergies (allergic to more than 2 kinds of food or medicine);
  • 7. The last 3 months participated in other clinical trials of drugs.

研究者

发起方
The First Affiliated Hospital of Guangzhou University of Chinese Medicine

相似试验